Brain scans reveal clues to alcoholism risk in Family-History study

NCT ID NCT05203965

Recruiting now Knowledge-focused Sponsor: Yale University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study at Yale University is investigating how the drug mavoglurant affects brain activity in people with a family history of alcoholism. Researchers will give 80 participants a single dose of mavoglurant or a placebo and use MRI scans to measure brain responses to reward and alcohol-related cues. The goal is to better understand the brain chemistry behind alcoholism risk, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Mavoglurant
What this could lead to: If successful, this study could help explain why some people are more vulnerable to alcoholism, potentially pointing toward new prevention strategies.
What could go wrong: This is a very early, small study (80 people) using only a single dose. It is designed to understand brain mechanisms, not to test a treatment, so it may not lead directly to any therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALCOHOL USE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alcohol abuse

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FAMILIAL ALCOHOLISM VULNERABILITY

Contacts and locations

Locations

Hartford Hospital
RECRUITING

Hartford, Connecticut, 06106, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.